-
公开(公告)号:EP3697889A1
公开(公告)日:2020-08-26
申请号:EP18868400.5
申请日:2018-10-19
-
公开(公告)号:EP3179393B1
公开(公告)日:2020-07-08
申请号:EP16191856.0
申请日:2013-01-28
申请人: Genomic Health, Inc.
-
公开(公告)号:EP3434201B1
公开(公告)日:2020-06-24
申请号:EP18195811.7
申请日:2011-02-17
申请人: LifeCell Corporation
发明人: STEVENSON, Eric , SUN, Wendell , BARERE, Aaron
-
公开(公告)号:EP3655031A1
公开(公告)日:2020-05-27
申请号:EP18752341.0
申请日:2018-07-20
发明人: BASH, Margaret , MATTHIAS, Kathryn
IPC分类号: A61K39/095 , A61P31/04
-
公开(公告)号:EP3270965B1
公开(公告)日:2020-05-06
申请号:EP16765773.3
申请日:2016-03-17
-
公开(公告)号:EP3622974A1
公开(公告)日:2020-03-18
申请号:EP19204646.4
申请日:2012-11-08
申请人: LifeCell Corporation
发明人: OWENS, Rick , XU, Hui , SUN, Wenquan
IPC分类号: A61L31/00
摘要: Acellular tissue matrix compositions for use in tissue approximation are provided. Also provided are methods for making and using the compositions to approximate tissue.
-
公开(公告)号:EP3622821A1
公开(公告)日:2020-03-18
申请号:EP19202040.2
申请日:2014-05-15
摘要: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
-
公开(公告)号:EP3066118B1
公开(公告)日:2020-01-08
申请号:EP14805427.3
申请日:2014-11-06
发明人: ORENTAS, Rimas , MACKALL, Crystal
IPC分类号: C07K14/725 , C07K16/30 , C07K16/46
-
公开(公告)号:EP3583201A1
公开(公告)日:2019-12-25
申请号:EP18754542.1
申请日:2018-02-13
发明人: SOTO-GUTIERREZ, Alejandro , MASHIMO, Tomoji , COLLIN DE I'HORTET, Alexandra, Sylvie , ALVAREZ, Eduardo, Cervantes , LEPE, Jorge, Guzman , HANDA, Kan , TAKEISHI, Kazuki , WANG, Yang , POPOVIC, Branimir
IPC分类号: C12N5/074 , A61K35/407 , A01K67/027
-
公开(公告)号:EP3581214A1
公开(公告)日:2019-12-18
申请号:EP19187888.3
申请日:2009-06-04
申请人: LifeCell Corporation
发明人: Sun, Wendell
摘要: A method of producing a modified acellular tissue matrix (mATM) from an acellular tissue matrix (ATM), where the mATM has a reduced stretchiness relative to the ATM, without substantially compromising its associated structural or functional integrity. The method includes providing an acellular tissue matrix (ATM) and exposing the ATM to elastase for a period of time.
-
-
-
-
-
-
-
-
-